Arvind Remedies Peer Comparison
NSE: ARVINDREM | BSE: 531823
₹4.70
As on 13-Jun-2016IST
Market cap
₹32 Cr
Revenue (TTM)
₹12 Cr
P/E Ratio
--
P/B Ratio
-0.2
Div. Yield
0 %
| Arvind Remedies | Acutaas Chemicals | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
32 | 32,591 | 35,535 | 31,872 | 28,572 |
Revenue (₹ Cr) |
12 | 1,593 | 3,751 | 9,779 | 2,100 |
Net Profit (₹ Cr) |
-137.36 | 438.64 | 405.00 | -270.51 | 324.79 |
Net Margin (%) |
-1,121.27 | 27.16 | 10.48 | -2.71 | 15.36 |
RoE (%) |
-- | 25.02 | 7.91 | -2.55 | 24.02 |
Price to Earnings |
-- | 74.21 | 86.67 | -- | 87.96 |
Price-To-Book |
-0.20 | 17.55 | 6.89 | 3.91 | 20.17 |
Income Statement (₹ Cr)
| Arvind Remedies | Acutaas Chemicals | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Operating Revenue
|
962.68 | 76.11 | 4,830.36 | -- | 41.58 |
|
Total Income
|
963.22 | 76.68 | 4,914.64 | -- | 41.73 |
|
Total Expenditure
|
781.32 | 69.99 | 3,850.53 | -- | 30.00 |
|
EBITDA
|
181.36 | 6.12 | 979.83 | -- | 11.59 |
|
Depreciation
|
14.34 | 0.80 | 139.92 | -- | 3.35 |
|
EBIT
|
167.03 | 5.32 | 839.91 | -- | 8.24 |
|
Interest
|
78.51 | 1.58 | 83.35 | -- | 2.34 |
|
Other Income
|
0.54 | 0.56 | 84.28 | -- | 0.14 |
|
Exceptional Items
|
-- | -- | 49.83 | -- | -- |
|
Profit before Tax
|
89.05 | 4.31 | 890.67 | -- | 6.04 |
|
Provision for Tax
|
28.69 | 1.44 | 47.88 | -- | 1.54 |
|
Profit after Tax
|
60.36 | 2.86 | 842.79 | -- | 4.50 |
Liabilities (₹ Cr)
| Arvind Remedies | Acutaas Chemicals | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
283.06 | 10.77 | 3,581.47 | -- | 44.83 |
|
Minority Interest
|
4.85 | -- | 136.17 | -- | -- |
|
Non-Current Liabilities
|
288.00 | 1.29 | 1,161.18 | -- | 10.36 |
|
Current Liabilities
|
547.46 | 26.33 | 1,743.20 | -- | 21.34 |
|
Total Liabilities
|
1,123.36 | 38.71 | 6,622.02 | -- | 76.53 |
Assets (₹ Cr)
| Arvind Remedies | Acutaas Chemicals | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
433.26 | 7.38 | 3,266.10 | -- | 51.75 |
|
Current Assets
|
690.11 | 31.01 | 3,355.92 | -- | 24.78 |
|
Total Assets
|
1,123.36 | 38.71 | 6,622.02 | -- | 76.53 |
|
Total Debt*
|
640.97 | 12.17 | 1,906.08 | -- | 21.09 |
|
Net Current Assets
|
142.65 | 4.68 | 1,612.72 | -- | 3.44 |
|
Contingent Liabilities
|
1.20 | -- | 267.40 | -- | 4.70 |
Cashflow (₹ Cr)
| Arvind Remedies | Acutaas Chemicals | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-65.08 | -0.21 | 1,476.29 | -- | 6.29 |
|
Cash Flow from Investing Activities
|
-24.64 | -2.00 | -851.62 | -- | -5.46 |
|
Cash from Financing Activities
|
71.24 | 2.17 | -601.32 | -- | -0.58 |
|
Net Cash Inflow / Outflow
|
-18.48 | -0.04 | 23.35 | -- | 0.25 |
Ratios
Profitability Ratios
| Arvind Remedies | Acutaas Chemicals | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
ROCE (%)
|
20.48 | 29.97 | 18.98 | -- | 13.38 |
|
ROE (%)
|
26.81 | 30.26 | 30.04 | -- | 19.08 |
|
ROA (%)
|
6.07 | 8.85 | 13.36 | -- | 6.16 |
|
EBIT Margin (%)
|
18.90 | 8.78 | 22.03 | -- | 28.21 |
|
Net Margin (%)
|
6.27 | 3.74 | 17.15 | -- | 10.78 |
|
Cash Profit Margin (%)
|
7.33 | 4.81 | 20.32 | -- | 18.86 |
Growth Ratios
| Arvind Remedies | Acutaas Chemicals | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
36.34 | 37.10 | -13.89 | -- | 12.11 |
|
EBIT Growth (%)
|
28.76 | 30.95 | -49.66 | -- | 21.82 |
|
Net Profit Growth (%)
|
34.25 | 39.55 | -46.64 | -- | 58.36 |
|
EPS Growth (%)
|
-4.56 | 39.55 | -56.04 | -- | 58.36 |
|
Book Value Growth (%)
|
57.80 | 32.03 | 36.37 | -- | 21.09 |
Valuation Ratios
| Arvind Remedies | Acutaas Chemicals | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Price / Earnings
|
5.03 | 0.00 | 6.59 | -- | 0.00 |
|
Price / Book Value
|
1.07 | 0.00 | 1.55 | -- | 0.00 |
|
Dividend Yield (%)
|
1.85 | -- | 2.19 | -- | -- |
|
EV/EBITDA
|
5.11 | 2.02 | 5.73 | -- | 3.52 |
|
Market Cap (₹ Cr)
|
293.96 | 0.00 | 5,016.58 | -- | 0.00 |
Solvency Ratios
| Arvind Remedies | Acutaas Chemicals | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Debt to Equity
|
2.33 | 1.13 | 0.54 | -- | 0.47 |
|
Short term debt to equity ratio
|
1.22 | 0.84 | 0.06 | -- | 0.23 |
|
Current Ratio
|
1.26 | 1.18 | 1.93 | -- | 1.16 |
|
Quick Ratio
|
0.90 | 0.75 | 1.36 | -- | 1.11 |
|
Interest Coverage
|
2.13 | 3.73 | 11.69 | -- | 3.58 |
Operating Efficiency Ratios
| Arvind Remedies | Acutaas Chemicals | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
36.39 | 17.81 | 9.96 | -- | 33.85 |
|
Asset Turnover
|
1.02 | 2.35 | 0.77 | -- | 0.57 |
|
Receivable days
|
109.13 | 58.46 | 54.33 | -- | 106.93 |
|
Inventory Days
|
58.18 | 41.85 | 77.43 | -- | 10.49 |
|
Payable days
|
41.26 | 91.25 | 120.43 | -- | 213.33 |
|
Cash Conversion Cycle
|
126.04 | 9.06 | 11.32 | -- | -95.91 |